Update of pharmacotherapy for premature ejaculation / 中华男科学杂志
National Journal of Andrology
;
(12): 449-452, 2007.
Artigo
em Chinês
| WPRIM
| ID: wpr-297704
ABSTRACT
Premature ejaculation (PE) is one of the most common sexual dysfunction problems, which has significant adverse effects on the life quality of the patients. Behavioral therapies have been the mainstay of PE management for many years. However, there is inadequate evidence for their long-term benefit. There are currently no medications licensed specifically for the treatment of PE. Current " off-label" pharmacotherapeutic approaches include topical anesthetics, phosphodiesterase-5 inhibitors, and serotonin reuptake inhibitors, all of which, however, fall short of the ideal therapy for PE. In the absence of a cure, the ideal treatment that researches aim at should be tolerable, effective from the first dose, rapid in onset of action, fast in elimination, and available as an oral medication. It is anticipated that agents being developed for the specific indication of PE will come closer to this ideal than the existing pharmacotherapeutic approaches.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Disfunções Sexuais Fisiológicas
/
Benzilaminas
/
Inibidores Seletivos de Recaptação de Serotonina
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Naftalenos
Limite:
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS